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ABSTRACT 
Viperin participates in the cell’s innate 
immune response against a number of viruses. 
Viperin mRNA is a substrate for 
endoribonucleolytic cleavage by RNase MRP and 
mutations in the RMRP snoRNA subunit of the 
RNase MRP complex cause cartilage-hair 
hypoplasia (CHH), a human developmental 
condition characterized by metaphyseal 
chondrodysplasia and severe dwarfism. It is 
unknown how CHH-pathogenic mutations in 
RMRP snoRNA interfere with skeletal 
development and aberrant processing of RNase 
MRP substrate RNAs is thought to be involved. 
We hypothesized that viperin plays a role in 
chondrogenic differentiation and discovered that 
viperin is expressed in differentiating 
chondrocytic cells, regulates their protein 
secretion and outcome of chondrogenic 
differentiation through influencing TGF-
β/SMAD2/3 activity via CXCL10. Disturbances 
in this viperin-CXCL10-TGF-β/SMAD2/3 axis 
were also found in CHH chondrocytic cells. Our 
data demonstrates that the anti-viral protein 
viperin controls chondrogenic differentiation by 
influencing secretion of soluble proteins and for 
the first time identifies a molecular route that may 
clarify impaired chondrogenic differentiation of 
CHH patient cells. 
 
 
INTRODUCTION  
Viperin, also known as RSAD2, is an 
interferon-inducible and evolutionary conserved 
protein that participates in the cell’s innate 
immune response against a number of viruses. 
Viperin localizes to the cytosolic face of the 
endoplasmic reticulum (ER), mitochondria and 
lipid droplets. It is described to exert its antiviral 
properties via several pathways, including 
inhibition of soluble protein secretion, alterations 
of mitochondrial energy metabolism, inhibition 
of virus replication in lipid droplets and 
modulation of cellular signaling events (1). The 
mRNA of viperin was identified as a substrate for 
endoribonucleolytic cleavage by the RNase MRP 
small nucleolar ribonucleoprotein complex (2). 
Mutations in the RMRP gene, which encodes the 
essential small nucleolar (snoRNA) subunit of the 
RNase MRP complex, are known to be the cause 
of the human genetic disease cartilage-hair 
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hypoplasia (3,4) (CHH: OMIM #250250). A 
major phenotypic hallmark of CHH is impaired 
skeletal development characterized by 
metaphyseal chondrodysplasia, leading to a 
severe form of dwarfism (5). Growth plates are 
central drivers in the formation of the skeleton 
and their endochondral ossification depends on a 
tightly orchestrated continuing process of 
chondrogenic differentiation, ultimately resulting 
in longitudinal growth of the long bones (6). 
Although a number of RNase MRP substrates 
have been identified in man (2,4,7-9), including 
viperin, there is a major lack of studies 
investigating the role of RNase MRP substrate 
RNAs in development, and in chondrogenic 
differentiation in particular. It is expected that 
insight into the involvement of RNase MRP 
substrates in chondrogenic differentiation will 
provide insight into the molecular mechanism 
leading to impaired skeletal development in 
CHH. In concert with viperin mRNA as a 
substrate for RNase MRP cleavage, viperin 
expression levels have been described to be 
increased after knockdown of protein 
components of the RNase MRP complex in HEp-
2 cells (2), in leukocytes of CHH patients (10) and 
recently we demonstrated that viperin expression 
is also upregulated after knockdown of RMRP 
RNA in chondrogenic differentiating ATDC5 
cells(11). Since increased viperin expression as a 
result of interference with RNase MRP function 
appears to be conserved amongst several cell 
types, we hypothesized that viperin regulates the 
course of chondrogenic differentiation. In this 
study we examined the expression of viperin, 
determined its role in chondrocyte protein 
secretion, and investigated its crosstalk with the 
TGF-β/SMAD2/3 signaling pathway in 
chondrogenic differentiation. We discovered that 
viperin is expressed in differentiating 
chondrocytic cells, regulates their protein 
secretion and impacts the outcome of the 
chondrogenic differentiation program through 
influencing TGF-β/SMAD2/3 activity via 
CXCL10. Our data for the first time shows that 
the anti-viral protein viperin regulates 
chondrogenic differentiation by influencing the 
secretion of soluble proteins and highlights its 
involvement in impaired chondrogenic 
differentiation in CHH patient cells. 
 
 
RESULTS 
 
Viperin protein is expressed throughout 
chondrocyte differentiation 
To investigate whether viperin is 
expressed during early chondrogenic 
differentiation, tissue sections were prepared 
from E15.5 mouse embryos. Expression of 
viperin was detected in growth plate 
chondrocytes throughout the developing growth 
plate, with highest expression levels in 
proliferating and terminally differentiating 
hypertrophic chondrocytes (Figure 1A). Cells in 
the upper zone of the growth plate displayed 
dispersed viperin positivity; viperin expression 
was either barely detectable in individual cells, 
was weakly expressed, or was relatively high 
expressed in individual cells (Figure 1B).  
We further interrogated potential viperin 
expression during chondrogenic differentiation of 
the ATDC5 cell line (12,13) and of primary 
human bone marrow stem cells (hBMSCs) (14). 
Chondrogenic differentiation of ATDC5 follows 
a well-defined cellular differentiation program 
with temporally increasing Sox9 and Col2a1 
levels (Figure 2A/B) and increasing levels of 
Runx2 and Col10a1 (Figure 2C/D). During the 
first 3 days of ATDC5 chondrogenic 
differentiation viperin mRNA expression was 
hardly detectable (Figure 2E). From day 4 
through day 14 (the latest time point tested), 
viperin mRNA expression was induced as 
compared to undifferentiated ATDC5 cells (t=0), 
and with a prominent peak expression at day 5 
and 6 in differentiation. Similar expression 
dynamics were observed for viperin protein 
expression in these chondrogenic cultures (Figure 
2F). During chondrogenic differentiation of 
hBMSCs (COL2A1 and COL10A1 mRNA 
expression in Figure 2G/H), peak induction of  
viperin mRNA expression was detected at day 7 
of differentiation (Figure 2I), which is in 
agreement with viperin expression during 
ATDC5 chondrogenic differentiation. 
Collectively these data show that developing 
chondrocytes express viperin in vivo and in vitro; 
with undetectable to low expression in the early 
differentiation phase and a profoundly increased 
expression later in differentiation.  
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Viperin knockdown reduces, while viperin 
overexpression increases protein secretion  
Previous work by Cresswell and 
colleagues (15) showed that viperin regulates 
protein secretion from the ER and it has been 
suggested that this is one of the mechanisms by 
which viperin confers its cellular anti-viral 
activity. Since there is no other cell biological 
role identified for viperin so far that could explain 
its expression in differentiating chondrocytes, we 
postulated that viperin regulates protein secretion 
in differentiating chondrocytes. To investigate 
total protein secretion in relation to viperin levels 
we introduced a secretable Gaussia-luciferase 
(pGluc-CMV) at either day 3 or 5 in ATDC5 
differentiation, followed by transfection of either 
a viperin siRNA duplex or a p3xFLAG-viperin 
plasmid at day 4 or 6 in differentiation, followed 
by sampling at day 5 or 7, respectively. Reduced 
expression of viperin at day 5 or 7 in 
differentiation was demonstrated upon siRNA-
mediated knockdown (Figure 3A) and ectopic 
expression of FLAG-viperin was confirmed at 
same time points (Figure 3A). Bioluminescent 
analyses showed that the amount of secreted 
Gaussia-luciferase was reduced following viperin 
knockdown and increased with viperin 
overexpression (Figure 3B). This was the case at 
both day 5 and 7 of differentiation. These data 
indicate that overall cellular protein secretion 
responds to changing viperin levels during 
chondrogenic differentiation. 
 
The viperin-controlled secretome influences 
chondrogenic differentiation 
Considering the central role secreted 
signaling molecules play during chondrogenic 
differentiating (6,16), we next questioned 
whether the observed viperin-controlled protein 
secretion plays a role in determining the 
chondrogenic outcome of the differentiation 
process via control over the chondrocyte’s 
secretome. We investigated this possibility by 
reducing endogenous viperin levels or 
overexpressing viperin in differentiating ATDC5 
chondrocytes and collecting conditioned media 
(CM) from these donor cultures. These CM were 
subsequently used to differentiate new ATDC5 
cultures. Altered chondrogenic capacity of these 
cultures would reveal whether reduced or 
increased viperin levels during chondrogenic 
differentiation differentially influence the 
chondrocyte’s secretome with downstream 
consequences for chondrogenic differentiation. 
Knockdown or over-expression of viperin was 
confirmed in the donor cultures from which CM 
were obtained (Figure 4A). Differentiation of 
ATDC5 cells in CM obtained from donor cultures 
in which viperin levels were reduced led to an 
overall increase in chondrogenic capacity, 
evidenced by increased expression of Sox9, 
Col2a1, Runx2, Col10a1 and Alpl (Figure 4B). 
Reciprocally, CM obtained from differentiating 
ATDC5 donor cultures in which viperin levels 
were over-expressed, displayed an inhibitory 
effect on the chondrogenic differentiation 
capacity, evidenced by reduced Sox9, Col2a1, 
Runx2, Col10a1 and Alpl expression (Figure 4C). 
The stimulatory and inhibitory actions of these 
CM on chondrogenic differentiation were further 
confirmed by determination of the 
glycosaminoglycan (GAG) content of these 
cultures. Differentiation of ATDC5 in CM 
obtained from donor cultures with reduced 
viperin levels caused an increased GAG content, 
while differentiation of ATDC5 in CM obtained 
from donor cultures in which viperin was over-
expressed led to a reduced GAG content (Figure 
4D). These results together indicate that 
alterations in viperin levels during chondrogenic 
differentiation change the cell’s secretome with 
important functional consequences for 
differentiation.  
 
Differential CXCL10 levels in viperin 
knockdown and overexpression secretomes 
Since media obtained from donor 
cultures with reduced or over-expressed viperin 
levels enhance or inhibit chondrogenic 
differentiation (respectively), we postulated that 
this was caused by a differential protein 
composition of their secretomes. To determine 
the differential proteome of the conditioned 
culture supernatants obtained from differentiating 
ATDC5 cultures with reduced or over-expressed 
viperin levels, we undertook a label-free mass-
spectrometry proteomics approach using liquid 
chromatography tandem mass spectrometry (LC-
MS/MS). When comparing the conditioned 
culture supernatants of differentiating ATDC5 
cultures in which a scrambled siRNA was 
transfected or in which viperin levels were 
Viperin in chondrogenic differentiation 
Revision JBC/2018/003772 
4 
 
reduced using the viperin siRNA (Figure 5A), we 
identified six protein species that were 
differentially expressed in the CM (Figure 5C). 
When comparing the conditioned culture 
supernatants of differentiating ATDC5 cultures in 
which an empty FLAG-vector was transfected or 
in which viperin levels were over-expressed 
using the FLAG-viperin plasmid (Figure 5B), we 
identified eight differentially expressed proteins 
in the CM (Figure 5C). Interestingly, CXCL10 
(grey highlighted in Figure 5C) was the only 
protein species that was detected in both 
differential secretome proteomes. CXCL10 was 
decreased in CM obtained from cultures in which 
viperin levels were reduced and was increased in 
conditioned medium obtained from cultures in 
which viperin levels were over-expressed. 
Differential CXCL10 protein levels in these 
culture supernatants were independently 
confirmed by ELISA (Figure 5D). Since 
expression of both viperin and CXCL10 are 
interferon-dependent (1,17) (supplementary 
Figure 1), we next verified CXCL10 secretion 
dynamics during chondrogenic differentiation of 
ATDC5. Using an ELISA, supernatant samples 
from cultures in Figure 2 were analyzed for 
CXCL10 protein levels and we found that 
CXCL10 levels in culture supernatant (Figure 
5E) during ATDC5 chondrogenic differentiation 
mirrored viperin expression dynamics (Figure 
2E/F). Data together demonstrates that alterations 
in viperin levels during chondrogenic 
differentiation lead to specific differences in the 
protein composition of the chondrocyte’s 
secretome, with CXCL10 a shared factor between 
the differential viperin-dependent secretomes. 
 
CXCL10 inhibits chondrogenic differentiation 
Conditioned culture medium obtained 
from differentiating ATDC5 cultures in which 
viperin levels were over-expressed was found to 
inhibit chondrogenic differentiation. Besides a 
limited number of other DE proteins, CXCL10 
was the only shared protein species that was 
differentially present in the viperin-dependent 
secretomes and was increased in viperin over-
expression culture supernatant. We therefore 
postulated that CXCL10 contributes to the 
inhibitory action on chondrogenic differentiation 
of the viperin over-expression culture supernatant 
(Figure 4C). To determine whether CXCL10 
inhibits chondrogenic differentiation, 
differentiating ATDC5 cultures were exposed to 
exogenously added mCXCL10 from day 5 of 
differentiation until day 7 of differentiation (the 
main time frame in which we observed peak 
expression of viperin and peak CXCL10 
concentrations; Figure 2E/F and Figure 5E). 
Analysis showed that exogenously added 
mCXCL10 attenuated chondrogenic 
differentiation, evidenced by decreased 
expression of Sox9, Col2a1, Runx2, Col10a1 and 
Alpl (Figure 6A). To verify the inhibitory action 
of CXCL10 in an independent model for 
chondrogenic differentiation, primary hBMSCs 
were differentiated into the chondrogenic lineage 
and exposed to increasing concentrations 
hCXCL10 from day 7 (peak viperin expression in 
hBMSC chondrogenic differentiation; Figure 2I) 
in chondrogenic differentiation onward. CXCL10 
inhibited chondrogenic differentiation of 
hBMSCs, evidenced by a decline of COL2A1 and 
COL10A1 mRNA expression (Figure 6B). These 
data indicate that viperin-dependent alterations in 
secreted CXCL10 levels influence chondrogenic 
differentiation capacity. 
 
Viperin levels and CXCL10 change SMAD2/3-
dependent TGF-β activity during chondrogenic 
differentiation of ATDC5  
The chondro-promotive and -inhibitory 
actions of CM obtained from donor cultures in 
which viperin expression was altered, as well as 
the chondro-inhibitory action of CXCL10, leads 
to an overall inhibited or increased expression of 
chondrogenic as well as hypertrophic marker 
genes. This indicates that the activity of a basic 
molecular pathway responsible for chondrogenic 
differentiation is altered and we therefore 
postulated the involvement of the major 
chondrogenic TGF-β/SMAD2/3 pathway. 
Viperin levels were either reduced or over-
expressed in differentiating ATDC5 cultures 
from day 5 to day 7 (Figure 7A), and CM were 
collected. Subsequently, proliferating ATDC5 
cells were used as a bioassay for SMAD2/3-
dependent TGF-β activity by transfection of a 
CAGA12-luciferase reporter plasmid (18,19). 
This TGF-β/SMAD2/3 reporter bioassay was 
then exposed to the above CM to determine their 
TGF-β/SMAD2/3-activity modulating action. 
We found that the CM obtained from 
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differentiating ATDC5 cultures in which viperin 
levels were reduced displayed a TGF-
β/SMAD2/3-activity promoting action (Figure 
7B). In contrast, CM obtained from 
differentiating ATDC5 cultures in which viperin 
levels were over-expressed displayed a TGF-
β/SMAD2/3-activity attenuating action (Figure 
7B). In concert with these findings Pai1 and 
SMAD7 mRNA levels (TGF-β/SMAD2/3 target 
genes(18,20)) were increased or decreased when 
ATDC5 was differentiated in CM (same as 
utilized in experiments shown in Figure 4B/C) 
from viperin knock-down or over-expression 
cultures, respectively (Figure 7C/D). 
Subsequently, we determined whether 
differential CXCL10 levels directly alter TGF-
β/SMAD2/3 activity during chondrogenic 
differentiation. ATDC5 cells were transfected 
with the CAGA12-luciferase reporter plasmid at 
day 5 in chondrogenic differentiation. Then, 
starting at day 6, cells were exposed to increasing 
concentrations recombinant murine CXCL10 and 
sampled for bioluminescent analyses 24 hours 
later. Data show that CXCL10 dose-dependently 
reduces TGF-β/SMAD2/3 reporter activity in 
these cultures (Figure 7E). Immunoblotting for 
SMAD2 phosphorylation (pSMAD2C) further 
showed that CXCL10 inhibits SMAD2 
phosphorylation during ATDC5 chondrogenic 
differentiation  (Figure 7F), which is in concert 
with the observed reduction of TGF-β/SMAD2/3 
reporter activity. Together these results 
demonstrate that alterations in viperin expression 
levels and CXCL10 impact SMAD2/3-dependent 
TGF-β activity during chondrogenic 
differentiation. This is in concert with the 
observed impact of these conditions on 
chondrogenic differentiation capacity (Figure 
4B/C/D and Figure 6). 
 
Impaired chondrogenic trans-differentiation of 
fibroblasts from CHH patients is associated with 
increased viperin and CXCL10 levels 
Mutations in the RMRP gene, encoding 
the essential RMRP snoRNA present in the 
RNase MRP macromolecular protein-RNA 
complex (4), are the cause of cartilage-hair 
hypoplasia-type human skeletal dysplasias (3,5). 
Viperin mRNA is a substrate for 
endoribonucleolytic degradation by RNase MRP 
(2). Taking into account the here identified 
chondrogenic regulatory role of a viperin-
CXCL10-TGF-β/SMAD2/3 axis, we postulated 
that a similar mechanism is active during the 
impaired chondrogenic trans-differentiation that 
we recently discovered in CHH fibroblasts (11). 
In ATDC5, reduction of RMRP snoRNA levels 
by transfection of an RMRP-specific siRNA 
(Figure 8A) indeed led to the induction of viperin 
expression ((11) and Figure 8B), recapitulating 
the endoribonucleolytic relationship between 
RNase MRP and its viperin mRNA substrate. A 
trans-differentiation protocol was used that drives 
dermal fibroblasts toward a chondrocyte-like 
phenotype (21). As described before (11), RMRP 
expression and chondrocytic trans-differentiation 
of CHH fibroblasts was impaired, as evidenced 
by inhibited expression of RMRP, SOX9, 
COL2A1, RUNX2, COL10A1 and ALPL (Figure 
8C). In concert with a CHH-associated 
pathological defective RNase MRP 
endoribonucleolytic activity, we found that 
viperin expression in chondrogenic trans-
differentiated CHH fibroblasts was increased 
(Figure 8D). This was accompanied with 
increased levels of secreted CXCL10 protein in 
these culture supernatants (Figure 8E) and 
decreased expression of the TGF-β target genes 
PAI1 and SMAD7 (Figure 8F). These data 
suggest that defective chondrogenic trans-
differentiation of CHH fibroblasts is caused by 
changes in TGF-β activity, induced by alterations 
in the viperin-CXCL10-TGF-β/SMAD2/3 axis. 
 
 
DISCUSSION 
Viperin expression was detectable early 
in ATDC5 and hBMSC chondrogenic 
differentiation and was highly induced at day 5-
6-7 of differentiation. In the majority of 
embryonal growth plate resting zone progenitor 
cells viperin expression was weak, representing 
the first days of in vitro chondrogenic 
differentiation. Interestingly, a sub-population of 
resting zone cells displayed high levels of viperin 
expression. Chondrogenic differentiation is 
synchronously initiated in cell culture, while this 
is not expected to be synchronous in the growth 
plate’s resting zone. We speculate that high 
viperin-expressing cells in the resting zone are a 
representation of asynchronous initiation of 
chondrogenic differentiation and that these cells 
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are in a similar differentiation phase as ATDC5 
and hBMSC cells during their early 
differentiation, when peak expression of viperin 
was observed. At later stages in chondrogenic 
differentiation viperin expression remained 
increased. This was also observed in growth 
plates, where proliferating and pre-hypertrophic 
chondrocytes are positive for viperin expression. 
Viperin expression is remarkably high in 
terminally differentiating growth plate 
chondrocytes. This was not observed in late 
ATDC5 and hBMSC differentiation time points 
tested. ATDC5 and hBMSCs are excellent in 
vitro models for chondrogenic differentiation 
(13). However these models do not enter 
apoptosis to fully terminally differentiate, as 
hypertrophic chondrocytes in the growth plate do. 
The spatiotemporal orchestration of cell 
differentiation in growth plates and the lack of 
such spatiotemporal cues in vitro may lead to the 
absence of this differentiation phase in in vitro 
chondrogenesis models and explain the observed 
difference in viperin expression compared to 
growth plates. 
Viperin was originally discovered as an 
interferon-inducible protein, suggesting that 
induction of viperin expression during 
chondrogenic differentiation may be driven by an 
intrinsic interferon-related signaling activity 
(further supported by data in supplementary 
Figure 1). Interferon-related signaling during 
chondrogenic differentiation is almost 
unexplored. Interferon-inducible proteins p202 
(22), p204 (23) and PKR (24) have been 
described to be important in chondrogenic 
differentiation. Inhibition of JAK rescues 
chondrogenic differentiation in osteoarthritis-like 
conditions (25) and IFN-γ has been demonstrated 
to inhibit transcription of the COL2A1 gene 
(26,27) in mature chondrocytes. STAT1 
expression was previously found specifically 
induced at day 7 in ATDC5 chondrogenic 
differentiation (24), supporting an intrinsically 
activated interferon signaling response as 
explanation for viperin induction at day 5-6-7. 
Different potential mechanisms to explain 
viperin’s antiviral actions include an Fe-S cluster-
dependent virus inhibitory action on lipid 
droplets (15,28), the inhibition of farnesyl 
diphosphate synthase leading to important 
changes in plasma membrane fluidity (29), the 
induction of a crystalloid ER (15), and the 
inhibition of protein secretion from the ER (15). 
Viperin has been shown to recruit IRAK1 and 
TRAF6 to lipid droplets in pDCs, leading to 
nuclear translocation of IRF7 and the production 
of type I interferons (30). These actions are 
specifically activated in response to viral 
infection and it is therefore surprising to find that 
in a non-viral context viperin is active as a 
regulator of cellular differentiation. Previously, 
alterations in viperin expression have been 
detected during adipogenic differentiation (31) 
and podocyte differentiation (32). Middle zone 
articular cartilage chondrocytes express higher 
amounts of viperin as compared to superficial 
zone chondrocytes (33) and viperin expression 
has been described in osteocytes (34). It is 
therefore likely that the consequences of viperin 
expression are not limited to differentiating 
chondrocytes. Until now it remained unexplored 
whether alterations in viperin levels could 
influence cellular differentiation processes. 
Following the findings by Cresswell and 
colleagues that viperin overexpression inhibits 
protein secretion from the ER in HepG2 and 293T 
cells (15), we examined whether this was also the 
case during chondrogenic differentiation. We 
found that also in chondrogenic differentiation 
viperin influences the rate of protein secretion, 
however in the opposite direction as compared to 
the findings reported by the Cresswell group. We 
speculate that due to different cell lineages, 
differentiation stages and the non-viral context, 
important differences occur in the viperin 
interactome (30) that change the manner by 
which viperin regulates protein secretion from the 
ER.  
We observed that total protein secretion alters in 
response to viperin levels, and until now no 
specificity has been reported for viperin-
regulated protein secretion. Therefore we expect 
that the protein species that we found 
differentially secreted following manipulation of 
viperin levels are either relatively unstable and 
inhibition of cellular protein secretion would thus 
cause a rapid decrease in the level of this species 
within the secretome, or are secreted in low 
abundance and increased protein secretion would 
rapidly lead to detectable differences in the level 
of this protein species in the secretome. In line 
with a viperin-mediated intrinsic interferon 
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response during chondrogenic differentiation, the 
CXCL10 we detected in our LC-MS/MS analyses 
is an interferon-inducible chemokine (IP-10). 
Interestingly, platelet-derived growth factor 
subunit A (PDGFA) was also found differentially 
expressed in the viperin over-expression 
secretome and PDGF has been described to 
synergistically act with IFN-γ to induce CXCL10 
expression in blood-derived macrophages (17). 
CXCL10 has previously been described to be 
expressed during ATDC5 chondrogenic 
differentiation (35), as well as during hBMSC 
chondrogenic differentiation (36). Our data 
demonstrate that CXCL10 inhibits chondrogenic 
differentiation and TGF-β signaling, which is 
fully in line with the inhibitory action of viperin-
overexpression CM on chondrogenic 
differentiation.  
Since we utilized conditioned media as a means 
to study the secretomic consequences of 
alterations in viperin expression during 
chondrogenic differentiation, we cannot 
distinguish paracrine from autocrine secreted 
signals. However, it is currently not clear why 
chondrogenic differentiation is regulated via 
viperin. Control over the activity of 
differentiation signals in the early differentiation 
phase may be required to enable the cell to 
undertake chromatin remodeling and coordinated 
transcriptomic reprogramming, before it can 
adopt a fully differentiated phenotype. We expect 
that temporal para- and/or autocrine viperin-
dependent CXCL10 secretion may aid in this by 
antagonizing TGF-β signaling and pacing cellular 
differentiation. Binding of CXCL10 with its 
CXCR3 receptor is known to activate PI3K in 
human airway epithelial cells (37) and recently, 
PI3K activity has been shown to be involved in 
attenuation of SMAD2/3 activity (38). Indeed we 
observed that CXCL10 inhibits phosphorylation 
of SMAD2, providing a potential mechanistic 
link between viperin-dependent CXCL10 
secretion and TGF-β-driven chondrogenic 
differentiation. Alternatively, crosstalk has been 
identified between IFN-γ and TGF-β signaling in 
which IFN-γ-dependent STAT1 activity 
antagonizes SMAD3-dependent TGF-β signaling 
(39).  
With a number of varying RNase MRP 
substrate RNAs it would not be likely that all 
aspects of CHH pathobiology are caused by 
defective processing of one specific substrate. 
Instead, defective processing of one or the other 
specific RNase MRP substrate RNA will have 
different implications for different tissue/cell 
types. CHH-related defective processing of 
viperin mRNA leads to aberrant viperin levels in 
chondrocytic cells as shown in this study. Viperin 
responses (40) and CXCL10 (41) have been 
implicated in T cell function and in a microarray 
mRNA profiling it was found that viperin was 
one of the highest differentially expressed genes 
upregulated in CHH leukocytes (10), together 
with an enrichment of other interferon-related 
genes. Since CHH also presents with defective 
immunity caused by T-cell deficiency (42) and 
together with our findings that viperin and 
CXCL10 regulate chondrogenic differentiation, 
is thus tempting to speculate that interferon-
related signaling through viperin, and via 
CXCL10, is an important aspect of the molecular 
mechanism leading to growth plate and T-cell 
defects observed in CHH. 
In conclusion our data link the antiviral 
protein viperin to chondrogenic development via 
a viperin-CXCL10-TGF-β/SMAD2/3 axis 
(Figure 9), and show that a similar molecular 
mechanism is deregulated in CHH chondrocytic 
cells. For the first time we identified a molecular 
route that may clarify impaired chondrogenic 
differentiation of CHH patient cells. 
 
 
EXPERIMENTAL PROCEDURES 
 
Immunohistochemistry (IHC) 
Five micrometer-thick formalin-fixed 
paraffin-embedded tissue sections were prepared 
from E15.5 NMRI mouse embryos. Use of the 
embryos was approved by the University of 
Freiburg (number X-14/10H), according to 
German law; and methods utilized to obtain the 
embryos were carried out in accordance with 
German law. Sections were deparaffinized in a 
xylene / ethanol series ending in PBS (136 mM 
NaCl (Merck Millipore, Darmstadt, Germany), 
2.7 mM KCl (Merck Millipore), 9.0 mM 
Na2PO4.H2O (Merck Millipore), 1.8 mM KH2PO4 
(Merck Millipore)). For antigen retrieval, 
sections were incubated in hot citrate buffer (1.8 
mM citric acid (Sigma-Aldrich, St. Louis, MO, 
USA) and 8.2 mM tri-sodium citrate (VWR 
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Prolabo, Amsterdam, the Netherlands)) for 30 
minutes. Endogenous peroxidase activity was 
inactivated using peroxidase-blocking solution 
(Dako, Troy, MI, USA). Slides were blocked with 
10% normal sheep serum in PBS-T (0.1% Tween 
20; Sigma-Aldrich). Primary antibody was 
incubated for 2 hours at room temperature. 
Mouse monoclonal anti-Viperin (Merck 
Millipore #MABF106) was used at a 1:200 
dilution. IgG2a (Dako) was used as an isotype 
control. Bound antibodies were detected with 
horseradish peroxidase (HRP)-conjugated rabbit 
anti-mouse secondary antibodies (Dako 
EnVision) for 30 minutes at room temperature. 
DAB chromogen substrate (Dako) was used for 
detection. Sections were counterstained with 
haematoxylin (Dako), dehydrated and mounted 
with histomount (Thermo Shandon, Waltham, 
MA, USA). Microphotographs were acquired 
using a Zeiss Axioscope A1.   
 
Cell culture and differentiation of ATDC5 
ATDC5 cells (12) (RIKEN BRC, Japan) 
were cultured in a humidified atmosphere at 
37oC, 5% CO2 in proliferation medium 
(DMEM/F12 (Invitrogen, Carlsbad, CA, USA), 
5% fetal calf serum (FCS) (Sigma-Aldrich), 1% 
antibiotic/antimycotic (Invitrogen), 1% non-
essential amino acids (NEAA) (Invitrogen)). 
Cells were tested negative for potential 
mycoplasma infection. To induce chondrogenic 
differentiation, cells were plated at 6,400 
cells/cm2. After 24 hours, chondrogenic 
differentiation was initiated by changing the 
medium to differentiation medium (proliferation 
medium supplemented with 10 µg/ml insulin 
(Sigma-Aldrich), 10 µg/ml transferrin (Roche, 
Basel, Switzerland), 30 nM sodium selenite 
(Sigma-Aldrich)). Differentiation medium was 
refreshed every two days for the first 10 days, and 
each day after day 10. In addition, ATDC5 cells 
were differentiated for 5 days and then exposed 
to 0.5 or 5 ng/ml recombinant murine CXCL10 
(Peprotech, Rocky Hill, NJ, USA, #250-16) until 
day 7 in differentiation. When ATDC5 cells were 
differentiated using conditioned media (CM), the 
CM was refreshed every other day.  
 
Cell culture and differentiation of hBMSCs 
Human bone marrow stem cells 
(hBMSCs) were obtained from residual iliac crest 
bone marrow aspirate from young, genetically 
healthy, individuals undergoing spinal surgery. 
Approval from the Maastricht University Medical 
Center Medical Ethical Committee (MEC) for the 
use of this material was obtained and assigned 
approval ID: MEC 08-4-056. Human BMSCs 
from four individual donors were isolated from 
the aspirate using Ficoll Paque (Amersham). 
Proliferation medium consisted of DMEM high-
glucose (Invitrogen), 10% FCS (ES-grade), 1% 
antibiotic/antimycotic and 1% NEAA. Passage 3 
cells were plated at 30,000 cells/cm2 in 
quadruplicates and chondrogenic differentiation 
was initiated the next day by changing to 
differentiation medium (proliferation medium 
supplemented with 1% ITS (Invitrogen), 50 
µg/ml L-ascorbic acid-2-phosphate (Sigma) and 
1 ng/ml TGFβ3 (R&D)) (14). Medium was 
changed every 2 days. Human CXCL10 
(Peprotech, Rocky Hill, NJ, USA) was used at 
indicated concentrations (0.5, 5, 50, 200 ng/ml). 
Cells were harvested in TRIzol at day 0, 2, 7, 14 
and 21 in differentiation for RNA isolation. 
 
Real time quantitative PCR (RT-qPCR) 
RNA was extracted from cells with 
TRIzol reagent (Invitrogen) and isolated by 
collecting the aqueous phase after phase 
separation. RNA was precipitated with 
isopropanol (30 minutes, -80oC) and centrifuged 
for 30 minutes at 15,000 RPM, 4oC. RNA pellets 
were washed with 80% ethanol and potential 
DNA contamination was removed by DNase I 
(Roche) treatment (1 hour, 37oC). After 
subsequent ethanol precipitation, RNA was 
dissolved in 15 µL DNase/RNase free water 
(Eurogentec, Seraing, Belgium). RNA quantity 
and purity were determined 
spectrophotometrically (Biodrop, Isogen Life 
Sciences, Utrecht, the Netherlands). Reverse 
transcription of RNA and RT-qPCR were 
performed as described previously (11). 
Housekeeping genes were β-Actin for ATDC5 
and CYCLOPHILIN for hBMSCs and human 
fibroblasts. Primer sequences are provided in 
Table 1. 
 
Immunoblotting 
Cells were washed three times with 0.9% 
NaCl. The cells were lysed in RIPA buffer (150 
mM NaCl, 1% NP-40, 0.5% sodium 
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deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5.0 
mM EDTA pH 8.0, 0.5 mM dithiothreitol (DTT), 
1 mM phenylmethylsulfonylfluoride (PMSF) and 
phosphatase inhibitor (PhosSTOP; Roche)). 
Samples were homogenized by sonication 
(Soniprep 150 MSE) using the following 
protocol: 14 cycles of 1 second sonication 
followed by a 1 second interval, amplitude 10. 
Cell debris was removed by centrifugation. Total 
protein concentration was determined with a 
BCA assay (Sigma-Aldrich). Samples were 
separated by gel electrophoresis and transferred 
to nitrocellulose membranes by electro-blotting. 
The following primary antibodies were used for 
immuno-detection: Mouse monoclonal anti-
Viperin (Merck Millipore #MABF106; 1:500 
dilution) and rabbit monoclonal anti-pSMAD2C 
(Cell Signaling Technologies #3108; 1:1000 
dilution). As controls mouse monoclonal anti-
Histone H3 (Abcam #24834; 1:1000 dilution), 
mouse monoclonal anti-alpha-Tubulin (Sigma-
Aldrich #T6074; 1:10,000 dilution) and mouse 
monoclonal anti-GAPDH (Fitzgerald #10R-
G109b; 1:5000 dilution) were used. HRP-
conjugated polyclonal rabbit anti-mouse (Dako) 
or HRP-conjugated swine anti-rabbit (Dako) was 
applied as a secondary antibody and the bound 
antibodies were detected by enhanced 
chemiluminescence (ECL).  
 
Transfection of siRNAs  
Chondrogenic differentiating ATDC5 cells were 
transfected (Pepmute; SignaGen Laboratories, 
Rockville, MD, USA; according to the 
manufacturer’s protocol) with 100 nM siRNA 
duplexes (custom synthesized by Eurogentec, see 
Table 2) targeting Viperin (on day 3 or day 5 of 
chondrogenic differentiation) or Rmrp RNA (on 
day -1, 2, and 5 of chondrogenic differentiation). 
Scrambled siRNA duplex was purchased from 
Eurogentec; REF: SR-CL000-005. 
 
Plasmids and transfection 
The viperin coding sequence, flanked by 
NotI - XbaI restriction sites, was custom-made 
synthesized by GeneCust (Ellange, Luxembourg) 
and originally cloned in pUC57 vector and 
sequence verified. The insert was then sub-cloned 
into the p3xFLAG plasmid (Promega, 
Southampton, UK) using the NotI - XbaI 
restriction sites, yielding the viperin 
overexpression plasmid (FLAG-viperin). On day 
4, 5 or 6 of ATDC5 chondrogenic differentiation, 
viperin expression was further induced in 6-well 
plates by transfection of 625 ng FLAG-viperin 
plasmid or an empty plasmid (FLAG-empty) as a 
control, using polyethylenimine (PEI; 
Polysciences, Warrington, PA, USA) transfection 
reagent. DNA and PEI were complexed for 10 
minutes at room temperature in DMEM/F12 
(1.88 µl PEI (1 µg/µl) per 625 ng construct per 
well) and added to the ATDC5 cells. To 
determine protein secretion 250 ng CMV 
promoter-driven secreted Gaussia luciferase 
plasmid (pGluc-CMV(43)) was co-transfected 
with 200 ng CMV promoter-driven firefly 
luciferase pGL4.20-CMV (control; Promega) on 
day 3 or day 5 of ATDC5 chondrogenic 
differentiation (6-well format), using PEI 
transfection reagent. Culture supernatant and 
cells were collected for bioluminescence analyses 
and Gaussia bioluminescence was normalized to 
the firefly signal. Viperin levels were either 
reduced or overexpressed in differentiating 
ATDC5 cultures from day 5 to day 7 and 
conditioned culture supernatants were collected. 
Subsequently, proliferating ATDC5 cells were 
used as a bioassay for SMAD3-dependent TGFβ 
activity by transfection with 500 ng CAGA12-
luciferase reporter plasmid (18) (kind gift of Dr. 
Dalmay (19)) and 125 ng pGluc-CMV (43) 
plasmid as a transfection control, using PEI 
transfection reagent. The proliferating ATDC5 
cells were then exposed to the above mentioned 
conditioned culture supernatants for 24 hours to 
determine the TGFβ/SMAD3-activity, where 
firefly bioluminescence was normalized to the 
Gaussia signal. The action of exogenously added 
CXCL10 on SMAD3-dependent TGF-β activity 
during chondrogenic differentiation was 
determined by transfecting day 5-differentiating 
ATDC5 cells in 6-well format with 500 ng 
CAGA12-luciferase reporter and 125 ng pGluc-
CMV plasmid as a transfection control, using PEI 
transfection reagent. Twenty-four hours later 
cells were exposed to 0.5, 5, 20 or 200 ng/ml 
recombinant murine CXCL10 (Peprotech #250-
16). At day 7 in differentiation, culture 
supernatant and cells were then collected for 
bioluminescence analyses and firefly 
bioluminescence was normalized to the Gaussia 
signal. pGluc-CMV (Gaussia luciferase), 
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pGL4.20-CMV (firefly luciferase) and CAGA-12 
(firefly luciferase) samples were all harvested for 
bioluminescence detection using the Dual 
Luciferase reporter assay system (Promega) as 
described by the manufacturer and measured on a 
Fluostar Omega plate reader (BMG Labtech, 
Ortenberg, Germany).  
 
Alcian Blue and Crystal Violet staining and 
quantification 
Cells were washed twice with 0.9% NaCl 
and fixated with 4% paraformaldehyde in PBS for 
10 minutes at room temperature. Fixated cells 
were washed 6 times with distilled water and air-
dried. Dried fixated cells were incubated for 30 
minutes at room temperature with respectively 
1% (m/v) Alcian Blue (Acros Organics, Geel, 
Belgium) in 0.1 M HCl or 0.1% (m/v) Crystal 
Violet (Sigma-Aldrich). Cells were washed six 
times with distilled water and allowed to air dry. 
Alcian Blue was extracted by incubation with 6 
M Guanidine-HCl (Sigma-Aldrich) for 2 hours 
on a plate shaker (IKA HS 260 Basic, IKA, 
Staufen, Germany). Crystal Violet was extracted 
by incubation with 10% acetic acid (VWR) for 15 
minutes on a plate shaker (IKA). Extracted 
Alcian Blue and Crystal Violet were quantified 
spectrophotometrically at 645 nm or 590 nm 
respectively using a plate reader 
(ThermoScientific Multiskan FC, Waltham, MA, 
USA). Crystal Violet (DNA content) was used as 
normalization for Alcian Blue 
glycosaminoglycan (GAG) content.  
 
In-solution tryptic digestion and mass 
spectrometry proteomics of media following 
viperin knockdown or overexpression 
At day 5 in ATDC5 chondrogenic 
differentiation, viperin expression was either 
reduced by transfection of a viperin-specific 
siRNA duplex or a scrambled control siRNA 
duplex; or viperin expression was further induced 
by transfection of the FLAG-viperin plasmid or 
the empty FLAG plasmid. Cells were then further 
differentiated until day 7 and conditioned 
medium (CM) was collected. During 
differentiation phenol-red free DMEM-F12 
(Invitrogen) was used in order to accommodate 
mass spectrometry analysis. To obtain sufficient 
amounts of CM, the experiment was 
simultaneously performed in three triplicates for 
each condition. Triplicates were then pooled to 
obtain three times scrambled siRNA duplex, three 
times viperin siRNA duplex, three times empty 
FLAG and three times FLAG-viperin 
overexpression CM samples. Two representative 
triplicates from each condition were utilized to 
confirm viperin knockdown and overexpression 
by means of immunoblotting. The CM was 
centrifuged for 5 minutes at 1200 rpm, to remove 
dead cells, and subsequently for 5 minutes at 
13,000 rpm to remove remaining debris. Then, 
Complete Ultra protease inhibitors (EDTA-free; 
Roche) were added. Samples were stored at -
80°C prior to downstream analysis. Protein 
concentrations of CM were calculated using the 
Bradford assay with Coomassie Plus™ protein 
assay reagent (Thermo Scientific, Rockford, IL, 
USA), read at 660 nm. In solution tryptic 
digestion was undertaken as previously described 
(44). Liquid chromatography tandem mass 
spectrometry (LC-MS/MS) analysis was 
performed on trypsin digests using an Ultimate 
3000 Nano system (Dionex, ThermoFisher 
Scientific, Waltham, MA, USA) on line to a Q-
Exactive Quadrupole-Orbitrap instrument 
(Thermo Scientific) (45). Proteins were identified 
using Peaks® 7 PTM software (Version 7, 
Bioinformatics Solutions, Waterloo, Canada), 
searching against the UniMouse database, with a 
false discovery rate (FDR) of 1%, a minimum of 
two unique peptides per protein and a confidence 
score > 50.  
 
Label-free quantification of mass spectrometry 
proteomics data 
Progenesis QI™ software (Version 4, 
Waters, Manchester, UK) was used to identify 
fold changes in protein abundance between 
scrambled siRNA duplex and viperin knockdown 
siRNA duplex and between the FLAG-empty and 
FLAG-viperin overexpression constructs as 
described previously(46). Only unique peptides 
were used for quantification, and with p-values 
<0.05, were considered to be differentially 
expressed (DE). 
 
CXCL10 ELISA 
To determine CXCL10 protein 
concentrations in media, the mouse CXCL10/IP-
10/CRG-2 DuoSet ELISA (R&D #DY466) and 
the human CXCL10/IP-10 Duoset ELISA (R&D 
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#DY266) were utilized according to the 
manufacturer’s protocol. Plates were 
colorimetrically measured on a ThermoScientific 
Multiskan FC plate reader (Waltham, MA, USA). 
 
Chondrogenic trans-differentiation of human 
dermal fibroblasts 
Human dermal fibroblasts (passage 7-9) 
from 3 CHH patients (RMRP alleles of CHH 
patients carried the following mutations: 
127G>A and 261 C>G; 4 C>T and 77C>T; 70 
A>G and 70A>G) and 3 healthy controls (Ethical 
permission was obtained from the medical ethical 
Institutional Review Board of Freiburg 
University Hospital and methods and 
experimental protocols to obtain dermal 
fibroblasts were carried out in accordance with 
the Freiburg University Hospital medical ethical 
Institutional Review Board, according to German 
law. Informed consent was obtained from all 
subjects) were hyperconfluently plated (100,000 
cells/cm2) in aggrecan-coated (Sigma-Aldrich; 
2.5 µg/cm2) wells as previously described(21). 
Cells were directly plated in trans-differentiation 
medium which consisted of 
DMEM/F12+Glutamax (Invitrogen), 10% FCS 
(PAA), 1% antibiotic/antimycotic (Invitrogen), 
1% NEAA (Invitrogen) + 1% ITS (Insulin, 
Transferrin, Selenium-Sodium Pyruvate; Life 
Technologies), 50 µg/ml ascorbic acid 2-
phosphate (Sigma-Aldrich) and 1 ng/ml human 
recombinant TGF-β3 (Life Technologies). Trans-
differentiation medium was refreshed on day 2 
and trans-differentiated cartilaginous nodules 
were harvested in TRIzol on day 3 of trans-
differentiation for RNA isolation. 
 
Statistics 
Gene expression, ELISA, colorimetric 
and bioluminescence data were statistically 
analyzed using GraphPad Prism 5 (La Jolla, CA, 
USA). A two-tailed independent samples t-test 
was performed relative to the corresponding 
control condition. Individual values are presented 
in graphs in dot plots and the p-values and mean 
± SEM are indicated in the figures. The number 
of biological replicates and number of repeated 
experiments are indicated in the figure legends. 
Statistical significance was defined as p<0.05. 
 
Data availability 
The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange 
Consortium 
(http://proteomecentral.proteomexchange.org) 
via the PRIDE partner repository (47) with the 
dataset identifier PXD006999 and 
10.6019/PXD006999. All other relevant data are 
available from the authors.  
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FIGURES AND FIGURE LEGENDS 
 
 
 
Figure 1. Viperin expression in the developing embryonal growth plate  
Five micrometer-thick formalin-fixed paraffin-embedded tissue sections were prepared from E15.5 
NMRI mouse embryos. Spatiotemporal expression of viperin was detected immunohistochemically. IgG2a 
was used as an isotype control. Overview of a representative immunohistochemically stained growth plate 
with IgG2a negative control in the insert (A). Indicated area from (A) enlarged. Black arrow indicates a 
representative cell with barely detectable viperin expression; grey arrow indicates a representative cell with 
weak viperin expression; yellow arrow indicates a representative cell with high viperin expression (B). 
Scale bars are indicated for magnification reference. 
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Figure 2. Viperin is expressed during chondrogenic differentiation of ATDC5 and hBMSCs 
ATDC5 cells were differentiated in the chondrogenic lineage for 14 days. Different stages of 
chondrogenic differentiation were confirmed by measuring mRNA expression of Sox9 (A), Col2a1 (B), 
Runx2 (C) and Col10a1 (D) by RT-qPCR. Expression of viperin mRNA during chondrogenic 
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differentiation was determined by RT-qPCR (E) and immunoblotting (F). Gene expression data (A-E) was 
normalized to β-actin mRNA levels and individual normalized values are presented in dot plots. For Viperin 
immunoblotting (F), Histone 3 (H3) was used as loading control. Primary human bone marrow 
mesenchymal stem cells (hBMSCs) of 4 human subjects were differentiated in the chondrogenic lineage 
for 1, 2, 7, 14 and 21 days. Chondrogenic differentiation was confirmed by measuring COL2A1 and 
COL10A1 mRNA expression (G/H). In same samples expression of VIPERIN mRNA was measured (I). 
hBMSC gene expression data (G/H) was normalized to CYCLOPHILIN mRNA levels. Individual data 
points in dot plots represent the average value of 4 biological replicates of one hBMSC donor. The p-values 
are indicated and NS = not significant. Presented graphs are representative examples of three independent 
experiments. Error bars represent mean ± SEM. 
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Figure 3. Viperin knockdown reduces, while viperin overexpression increases overall protein secretion 
A CMV promoter-driven secreted Gaussia luciferase plasmid (pGluc-CMV) was co-transfected 
with a CMV promoter-driven firefly luciferase pGL4.20-CMV on day 3 or day 5 of ATDC5 chondrogenic 
differentiation. Then, on day 4 or 6, viperin expression was either reduced by transfection of a viperin-
specific siRNA duplex (Viperin siRNA) or a scrambled control siRNA duplex (Scrambled siRNA); or 
viperin expression was further induced by transfection of a p3xFLAG-viperin plasmid (FLAG-Viperin) or 
the empty p3xFLAG plasmid (FLAG-empty). Reduced or induced viperin expression (normalized to β-
actin) was confirmed by RT-qPCR at day 5 or day 7 in differentiation (A) and individually presented in dot 
plots. Bioluminescence was assessed at day 5 or 7 in differentiation in culture supernatant (Gaussia 
luciferase) and cells (firefly luciferase). Gaussia bioluminescence was normalized to the firefly signal. 
Normalized relative light units (RLU) of controls were set at 1 and condition RLUs were calculated relative 
to the control RLUs and individually presented in dot plots (B). For statistical evaluation an independent 
samples t-test was performed relative to the corresponding controls using GraphPad Prism 5. Data are 
presented of 4 biological replicates. The p-values are indicated and error bars indicate mean ± SEM. 
Presented graphs are examples of 3 individual experiments.  
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Figure 4. The viperin secretome influences chondrogenic differentiation 
At day 5 in ATDC5 chondrogenic differentiation, viperin expression was either reduced by 
transfection of a viperin-specific siRNA duplex (Viperin siRNA) or a scrambled control siRNA duplex 
(Scrambled siRNA); or viperin expression was further induced by transfection of a p3xFLAG-viperin 
plasmid (FLAG-Viperin) or the empty p3xFLAG plasmid (FLAG-empty). Cells were then further 
differentiated until day 7 and viperin expression levels were determined (A). Conditioned culture 
supernatant (CM) from these donor cultures was harvested at day 7 and newly seeded ATDC5 cells were 
then differentiated with the CM supernatants for 7 days. RNA was isolated and Sox9, Col2a1, Runx2, 
Col10a1 and Alpl gene expression was determined in these samples (B/C). Glycosaminoglycan content 
(Alcian blue assay) was determined in ATDC5 cultures differentiated in CM supernatant from donor 
cultures in which viperin expression was reduced or further induced (D). RT-qPCR data was normalized to 
β-actin mRNA levels and individual normalized values are presented as dot plots. Glycosaminoglycan 
content data is presented as fold change relative to the corresponding control condition. For statistical 
evaluation an independent samples t-test was performed relative to the corresponding control condition 
using GraphPad Prism 5. The p-values are indicated and NS = not significant. All presented data were 
acquired from 4 biological replicates and error bars indicate mean ± SEM. Graphs are representative 
examples of 3 individual experiments.  
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Figure 5. The viperin secretome and CXCL10 
At day 5 in ATDC5 chondrogenic differentiation, viperin expression was either reduced by 
transfection of a viperin-specific siRNA duplex (Viperin siRNA) or a scrambled control siRNA duplex 
(Scrambled siRNA); or viperin expression was further induced by transfection of a p3xFLAG-viperin 
plasmid (FLAG-Viperin) or the empty p3xFLAG plasmid (FLAG-empty). Cells were then further 
differentiated until day 7 and viperin expression levels were determined (A/B). Immunoblots are shown for 
two independent representative examples. Culture supernatants from these day-7 cultures were collected 
and the protein secretome was determined by label-free LC-MS/MS. Differentially secreted extracellular 
protein species (control versus condition) with p<0.05 are shown (C). FC = Fold Change. In culture 
supernatants analyzed with LC-MS/MS, secreted CXCL10 levels were determined (D). In ATDC5 culture 
supernatants from Figure 2, secreted CXCL10 levels were determined (E). The p-values are indicated and 
error bars indicate mean ± SEM. 
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Figure 6. CXCL10 attenuates chondrogenic differentiation 
ATDC5 cells were differentiated and exposed to mCXCL10 from day 5 until day 7. RNA was 
isolated and expression of Sox9, Col2a1, Runx2, Col10a1 and Alpl mRNAs was determined (A). Human 
bone marrow mesenchymal stem cells (hBMSCs) were differentiated in the chondrogenic lineage for 7 days 
and exposed to hCXCL10 until day 21. RNA was isolated and expression of COL2A1 and COL10A1 
mRNAs was determined (B). ATDC5 data were acquired from 4 biological replicates, normalized to β-
actin mRNA levels and individual normalized values are presented in dot plots. hBMSC gene expression 
data was normalized to CYCLOPHILIN mRNA levels. Individual data points in dot plots represent the 
average value of 4 biological replicates of one hBMSC donor. For statistical evaluation an independent 
samples t-test was performed relative to the corresponding controls using GraphPad Prism 5. The p-values 
are indicated and error bars show mean ± SEM. The graphs are a representative example of 3 individual 
experiments. 
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Figure 7. TGF-β/SMAD2/3 activity is controlled by the viperin secretome and CXCL10  
At day 5 in ATDC5 chondrogenic differentiation, viperin expression was either reduced by 
transfection of a viperin-specific siRNA duplex (Viperin siRNA) or a scrambled control siRNA duplex 
(Scrambled siRNA); or viperin expression was further induced by transfection of a p3xFLAG-viperin 
plasmid (FLAG-Viperin) or the empty p3xFLAG plasmid (FLAG-empty). Cells were then further 
differentiated until day 7 and viperin expression levels were determined (A). Conditioned culture 
supernatants (CM) from these day-7 cultures were collected. Proliferating ATDC5 were used as a TGF-
β/SMAD2/3 bioassay by co-transfecting a CAGA-12 firefly luciferase TGF-β/SMAD3 reporter and pGluc-
CMV plasmid. The TGF-β/SMAD2/3 bioassay was then exposed to the CM supernatants for 24 hours and 
supernatant and cells were collected for bioluminescence analyses. Firefly bioluminescence was normalized 
to the Gaussia signal (B). Gene expression of downstream TGF-β target genes Pai1 and Smad7 was 
determined on samples from Figure 4B/C (C/D). ATDC5 cells were differentiated and co-transfected with 
a CAGA-12 firefly luciferase TGF-β/SMAD3 reporter and pGluc-CMV plasmid on day 5 in chondrogenic 
differentiation. At day 6 in differentiation cells were exposed to 0.5, 5, 50 or 200 ng/ml recombinant mouse 
CXCL10 for 24 hours until day 7. Culture supernatant and cells were collected for bioluminescence 
analyses. Firefly bioluminescence was normalized to the Gaussia signal (E). ATDC5 cells were 
differentiated until day 5 and then exposed to 0.5, 5, 50 or 200 ng/ml mouse CXCL10 until day 7. Protein 
extracts were separated by SDS-PAGE and electro-blotted on membranes, followed by pSMAD2C immuno 
detection. GAPDH was used as a loading control (F). All quantitative data were acquired from 4 biological 
replicates. RT-qPCR data were normalized to β-actin mRNA levels and individual normalized values are 
presented in dot plots. Bioluminescence data are presented as normalized RLUs. RLUs of controls were set 
at 1 and RLUs of conditions were calculated relative to the control RLUs. For statistical evaluation an 
independent samples t-test was performed relative to the corresponding controls using GraphPad Prism 5. 
The p-values are indicated and error bars represent mean ± SEM. Graphs are representative examples of 3 
individual experiments. 
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Figure 8. The viperin-CXCL10-TGF-β/SMAD2/3 axis is deregulated in chondrocytic CHH cells 
Rmrp RNA expression was reduced in ATDC5 cells by transfection of a specific siRNA duplex on 
day -1, day 2, and day 5 during chondrogenic differentiation. A scrambled siRNA was used as control. 
Samples were harvested for RT-qPCR analysis at day 0, 7 or 10 in differentiation. Expression of Rmrp (A) 
and viperin (B) was determined at indicated time points. Data was normalized to β-actin mRNA levels and 
individual normalized values are presented in dot plots. Data were acquired from 3 biological replicates. 
An independent samples t-test was performed relative to scrambled control using GraphPad Prism 5. The 
p-values are indicated and error bars represent mean ± SEM. Human dermal fibroblasts from three CHH 
patients (RMRP alleles of CHH patients carried following mutations: 127G>A and 261 C>G; 4 C>T and 
77C>T; 70 A>G and 70A>G) and three healthy controls were trans-differentiated into the chondrogenic 
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lineage by hyperconfluent plating in wells coated with Aggrecan (21,48). RNA was isolated at day 3 of 
trans-differentiation and gene expression of RMRP, SOX9, COL2A1, RUNX2, COL10A1 and ALPL 
mRNAs was determined (C). Gene expression of VIPERIN (D) and of PAI1 and SMAD7 (F) was 
determined in samples from (C). Supernatants were collected from these cultures and secreted CXCL10 
protein was determined with ELISA (E). Gene expression data from trans-differentiated fibroblasts was 
normalized to CYCLOPHILIN mRNA levels and individual normalized values are presented in dot plots. 
Secreted CXCL10 data are absolute concentrations (pg/mL) and presented in dot plots. For statistical 
evaluation independent samples t-tests were performed relative to healthy controls using GraphPad Prism 
5. The p-values are indicated. Error bars are mean ± SEM. Graphs are representative examples of three 
independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Viperin in chondrogenic differentiation 
Revision JBC/2018/003772 
27 
 
 
 
Figure 9. Model of the interactions between viperin and chondrogenic differentiation 
A schematic model of the interactions between viperin and chondrogenic differentiation, suggested 
by our results. Viperin regulates protein secretion and controls the level of secreted CXCL10. CXCL10 
inhibits TGF-β/SMAD2/3 activity, which in turn controls the level of chondrogenic differentiation. 
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TABLES 
 
Table 1. RT-qPCR primer sequences 
Gene Forward Reverse 
ALPL (Hs) CCGTGGCAACTCTATCTTTGG CAGGCCCATTGCCATACAG 
Alpl (Mm) CCGATGGCACACCTGCTT GGAGGCATACGCCATCACAT 
β-Actin (Mm) CCGAGCGCGAGATCGT TGGCCATCTCGTTCTCGAA 
COL2A1 (Hs) TGGGTGTTCTATTTATTTATTGTCTTCCT GCGTTGGACTCACACCAGTTAGT 
Col2a1 (Mm) TGGGTGTTCTATTTATTTATTGTCTTCCT GCGTTGGACTCACACCAGTTAGT 
COL10A1 (Hs) ATGATGAATACACCAAAGGCTACCT ACGCACACCTGGTCATTTTCTG 
Col10a1 (Mm) CATGCCTGATGGCTTCATAAA AAGCAGACACGGGCATACCT 
CYCLOPHILIN (Hs) TTCCTGCTTTCACAGAATTATTCC GCCACCAGTGCCATTATGG 
PAI1 (Hs) GTCTGCTGTGCACCATCCCCCATC TTGTCATCAATCTTGAATCCCATA 
Pai1 (Mm) ACGTCGTGGAACTGCCCTAC CAGCGATGAACATGCTGAGG 
RMRP (Hs) GAGAGTGCCACGTGCATACG ACGCTTCTTGGCGGACTTT 
Rmrp (Mm) ATACGAGGGACATGTTCCTTATCC TTGGCGGGCTAACAGTGACT 
RUNX2 (Hs) TGATGACACTGCCACCTCTG GCACCTGCCTGGCTCTTCT 
Runx2 (Mm) GACGAGGCAAGAGTTTCACC GGACCGTCCACTGTCACTTT 
SMAD7 (Hs) CCTTAGCCGACTCTGCGAACTA CCAGATAATTCGTTCCCCCTGT 
Smad7 (Mm) GCAACCCCCATCACCTTAGTC GTTTGAGAAAATCCATTGGGTATCTG 
SOX9 (Hs) AGTACCCGCACCTGCACAAC CGCTTCTCGCTCTCGTTCAG 
Sox9 (Mm) AGTACCCGCACCTGCACAAC TACTTGTAGTCCGGGTGGTCTTTC 
VIPERIN (Hs) CCAACCAGCGTCAACTATCACTT GGAAACAGAAGCCGCATTTG 
Viperin (Mm) TGCTATCTCCTGCGACAGCTT CCTTGACCACGGCCAATC 
Primer sequences were designed for Mus musculus (Mm) or Homo sapiens (Hs). 
 
Table 2. siRNA sequences 
siRNA Sense Anti-sense 
Viperin siRNA GGGAAGCAGAAAGAUUUCUdTdT AGAAAUCUUUCUGCUUCCCdTdT 
Rmrp siRNA CAUGUUCCUUAUCCUUUCGdTdT CGAAAGGAUAAGGAACAUGdTdT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Viperin in chondrogenic differentiation 
Revision JBC/2018/003772 
29 
 
 
 
SUPPLEMENTARY FIGURE 
 
 
 
 
 
 
Supplementary Figure 1. Inhibition of interferon signaling activity during ATDC5 chondrogenic 
differentiation inhibits secreted CXCL10 levels in culture supernant and attenuates viperin expression 
ATDC5 cells were differentiated into the chondrogenic lineage until day 6. Downstream interferon 
signaling activity was then inhibited for 24 hours until day 7. The JAK inhibitor Ruxolitinib was used at 1 
µM or 10 µM. The STAT inhibitor Fludarabine was used at 1.5 µM or 15 µM. Control was treatment with 
vehicle. At day 7 culture supernatant was collected and cells were harvested for total RNA isolation, 
followed by cDNA synthesis. In culture supernatants secreted CXCL10 protein levels were determined (A). 
Expression of viperin was determined by RT-qPCR Sox9 (B). Secreted CXCL10 data are absolute 
concentrations (pg/mL) and presented in dot plots. RT-qPCR data was normalized to β-actin mRNA levels 
and individual normalized values are presented in dot plots. All data were acquired from 3 biological 
replicates. An independent samples t-test was performed relative to control using GraphPad Prism 5. The 
p-values are indicated and error bars represent mean ± SEM. 
 
